



STEPPING **BEYOND** THE STATUS QUO IN HEART FAILURE

THE REVOLUTIONARY ROLE OF SGLT2 INHIBITION

OVERVIEW

This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF). Expert faculty will also examine new and emerging CVOT data for SGLT2 inhibitors, including recent approvals and guideline recommendations, and offer insights into how these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients. To reinforce these teaching points within the context of a collaborative approach, attendees will be engaged in a case-based discussion focused on key characteristics of an effective, integrated approach to HF management.

TARGET AUDIENCE

Cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants, focused on the integration of new and emerging CVOT data into clinical practice, with an emphasis on collaborative management of heart failure

AGENDA

5 min Welcome and Introductions
50 min Stepping Beyond the Status Quo In Heart Failure: The Revolutionary Role of SGLT2 Inhibition
5 min Questions and Answers

LEARNING OBJECTIVES

At the conclusion of this application-based activity, participants will be able to:

1. Explore the evolution of SGLT2 inhibition in the CVOT era and evaluate mechanisms linking T2D and heart failure (HF).
2. Appraise new and emerging CVOT data for antihyperglycemic agents and compare outcomes data across the type 2 diabetes (T2D) therapeutic classes.
3. Examine recently-reported CVOT data for SGLT2 inhibitors, and discuss ways that these agents are shifting the HF treatment paradigm and broadening horizons for both diabetic and nondiabetic patients.
4. Using a case-based format, recognize opportunities for cardiologists to collaborate with endocrinologists, primary care providers, and other members of the healthcare team, and identify key characteristics of an integrated approach to HF management.

FACULTY BIO



Muthiah Vaduganathan, MD, MPH
Activity Co-Chair
Harvard Medical School
Brigham and Women's Hospital
Cardiovascular Medicine
Boston, Massachusetts

Dr. Vaduganathan is a cardiologist at Brigham and Women's Hospital and Harvard Medical School (Boston, MA). He is interested in drug development and clinical trials of cardiometabolic therapies. He has authored or co-authored more than 275 peer-reviewed publications.

Dr. Vaduganathan serves on the editorial board of the European Journal of Heart Failure and JACC Heart Failure (Social Media / CME Editor). He serves on the ACCF/AHA Task Force on Performance Measures and is a co-chair on an FDA Think Tank on improving future clinical trials in HF. He participates as a Clinical Endpoints Committee member for ongoing advanced-phase trials in HF / post-MI LV dysfunction.

PLANNER AND FACULTY DISCLOSURES

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

PLANNERS

Bryan Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

PRESENTERS

Jarett Berry, MD—has disclosed that he is a consultant for AstraZeneca and Roche; he also receives grant/research support from Abott, NIH, and Roche.

Javed Butler, MD, MPH, MBA—has disclosed that he is a consultant for Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, Luitpold, Medtronic, Merck, Novartis, Relypsa, and Vifor.

Muthiah Vaduganathan, MD, MPH—has disclosed that he is a consultant for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim, and Relypsa and receives grant/research support from KL2/Catalyst Medical Research Investigator Training.

PEER REVIEWERS

Kim Birtcher, MS, PharmD, AACC, FNLA, BCPS-AQ Cardiology, CDE, CLS—has no relevant financial relationships to disclose in relation to the content of this activity.

Debra K. Moser, PhD, RN, FAAN—has no relevant financial relationships to disclose in relation to the content of this activity.

Ambarish Pandey, MD, MSCS—has no relevant financial relationships to disclose in relation to the content of this activity.

Scott Urquhart, PA-C, DFAAPA—has disclosed that he is a consultant for AstraZeneca, Dexcom, Novo Nordisk, and Sanofi. He is a member of the speakers' bureau for AstraZeneca and Novo Nordisk.

ACCREDITATION



In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE Credit



This activity was planned by and for the healthcare team, and learners will receive 1 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-008-L01-P).

Nursing (ANCC)

This activity is designated for 1.0 contact hour.

Physician Assistants (AAPA)

Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.



To receive an electronic copy of the attendee handbook please visit <https://www.ceconcepts.com/content/stepping-beyond-status-quo-heart-failure-revolutionary-role-sglt2-inhibition-6#group-tabs-node-course-default1> and click on the "Handout and Resources" link.

